Regorafenib
Nov. 30, 2024
Stivarga (Regorafenib) for Treating Metastatic Colorectal Cancer (mCRC) - Clinical Trials Arena Regorafenib | C21H15ClF4N4O3 | CID 11167602 - PubChem Regorafenib, multikinase inhibitor (CAS 755037-03-7) (ab216314) | Abcam Bayer's Stivarga® (regorafenib) Tablets Approved by U.S. FDA for Treatment of Patients with Locally Advanced, Unresectable or Metastatic GIST | Regorafenib
![Structure of Regorafenib. 4-(4-[{(4-Chloro-3-[trifluoromethyl]phenyl)... | Download…](https://www.researchgate.net/publication/264745710/figure/fig2/AS:601626498826243@1520450343311/Structure-of-Regorafenib-4-4-4-Chloro-3-trifluoromethylphenyl.png){kind=link}
![PDF] Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an …](https://d3i71xaburhd42.cloudfront.net/eb54674a887d293f092e2f58ac8ea03ff6557589/2-Figure1-1.png){kind=link}
